Physician profile
Matthew Budoff
NPI 1811967433
$3,617,189.27
in general payments reported to CMS, 2019-2025
61 companies · $542K in 2025
The $542K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $640K · 2020: $408K · 2021: $558K · 2022: $487K · 2023: $407K · 2024: $574K · 2025: $542K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.1M · Consulting Fee: $269K · Travel and Lodging: $126K · Food and Beverage: $28K · Honoraria: $20K · Education: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,078,194.00 |
| Consulting Fee | $268,922.72 |
| Travel and Lodging | $125,659.25 |
| Food and Beverage | $28,263.42 |
| Honoraria | $19,540.00 |
| Education | $2,519.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $439,400.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $437,332.71 | 2019-2025 | Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $415,909.09 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Esperion Therapeutics, INC. | $302,517.05 | 2020-2024 | Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $290,621.70 | 2021-2025 | Verquvo |
| Amgen INC. | $262,906.07 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $222,881.92 | 2019-2025 | Vascepa |
| Regeneron Healthcare Solutions, INC. | $200,142.59 | 2019-2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $186,290.89 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180,092.05 | 2019-2025 | Jardiance |
| Heartflow, INC. | $154,919.90 | 2019-2025 | Ffrct |
| Sanofi-Aventis U.S. LLC | $105,337.82 | 2019-2020 | |
| Pfizer INC. | $74,817.38 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69,263.46 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $52,634.14 | 2023-2024 | Inpefa |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43,394.26 | 2019-2025 | Leqvio |
| Seqirus USA INC | $26,990.92 | 2024 | |
| Eli Lilly and Company | $25,070.00 | 2020-2024 | Jardiance |
| Fukuda Denshi Co., Ltd. | $11,250.00 | 2021-2025 | Vs-2000 |
| Corcept Therapeutics | $10,956.00 | 2024-2025 | Korlym |
| Ionis Pharmaceuticals, INC. | $10,207.47 | 2025 | Olezarsen |
| Cleerly, INC. | $8,398.70 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| E.R. Squibb & Sons, L.L.C. | $7,326.86 | 2019-2023 | Camzyos |
| Abbvie INC. | $7,251.83 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $6,583.37 | 2021-2022 | |
| Agepha Pharma Fz LLC | $6,524.34 | 2025 | Lodoco |
| Genentech, INC. | $6,192.07 | 2024 | |
| Renalytix Ai, INC. | $6,000.00 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk As | $5,549.67 | 2022-2023 | |
| Abbott Laboratories | $5,377.82 | 2019-2021 | |
| Elucid Bioimaging INC | $5,282.88 | 2022-2024 | |
| Medicure Pharma INC. | $4,500.00 | 2019-2020 | |
| Actelion Pharmaceuticals, Ltd | $4,361.24 | 2022 | |
| Arineta, INC | $4,355.00 | 2023 | Spotlight |
| Idorsia Pharmaceuticals US INC | $3,540.00 | 2024 | Quviviq |
| Ge Healthcare | $3,478.86 | 2019-2025 | |
| Canon Medical Informatics, INC. | $3,000.00 | 2024-2025 | Vitrea Advanced Visualization, Vitrea V-Score |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,738.56 | 2019-2025 | Lifevest |
| Boehringer Ingelheim International Gmbh | $1,107.49 | 2019 | |
| United Imaging Healthcare North America LLC | $811.51 | 2024 | Next Generation Ct Systems |
| Fukuda Denshi Co., Ltd. | $750.00 | 2020 | |
| Astellas Pharma US INC | $254.66 | 2019-2022 | |
| Boston Scientific Corporation | $214.71 | 2020-2025 | General - Ultrasound |
| Medtronic, INC. | $187.02 | 2021-2025 | Symplicity G3 |
| Regeneron Pharmaceuticals, INC. | $151.45 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $98.38 | 2019-2021 | |
| Cook Medical LLC | $41.38 | 2022 | |
| Akcea Therapeutics, INC. | $36.04 | 2020 | |
| Invivyd INC | $31.36 | 2025 | Pemgarda |
| Kiniksa Pharmaceuticals, Ltd. | $30.24 | 2023 | Arcalyst |
| United Therapeutics Corporation | $23.45 | 2023 | Tyvaso |
| Bridgebio Pharma, INC. | $22.34 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $19.96 | 2019 | |
| Teleflex LLC | $12.32 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$583,434.63 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Budoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.